DGAP-News
Sangui BioTech International Inc.: Revenues improved in the first quarter of the 2015 financial year
DGAP-News: Sangui BioTech International Inc. / Key word(s): Interim
Report
Sangui BioTech International Inc.: Revenues improved in the first
quarter of the 2015 financial year
13.11.2014 / 12:00
---------------------------------------------------------------------
Sangui BioTech: Revenues improved in the first quarter of the 2015
financial year
Research and development for preparing and carrying out preclinical trials
Witten, Germany, November 13, 2014 - For the first quarter (as of September
30, 2014) of its 2015 financial year Sangui BioTech International, Inc.
reports revenues from product sales and royalties in the amount of
USD73,470 (Q1/2013: USD26,527). This is an improvement of 73% as compared
with the fourth quarter of the previous financial year (as of June 30,
2014).
Research and development expenses amounted to USD93,103 (Q1/2014:
USD36,308). The increase is due to preparing and carrying out preclinical
trials aimed at demonstrating the functionality of Sangui's technology with
respect to various indications. The net loss attributable to shareholders
of the parent company came to USD194,168 (Q1/2013: USD172.202), the cash
outflow from operations during the quarter amounted to USD207,675 (Q1/2013:
USD189,860).
Primarily due to the net loss for the quarter, our stockholders' equity
decreased by USD75,501 from USD7,276 at June 30, 2014 to a stockholders'
deficit of USD68,225 at September 30, 2014.
The complete quarterly report on Form 10-QSB is available at www.sec.gov
and www.sanguibiotech.com.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de
---------------------------------------------------------------------
13.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
296450 13.11.2014
Sangui BioTech: Revenues improved in the first quarter of the 2015
financial year
Research and development for preparing and carrying out preclinical trials
Witten, Germany, November 13, 2014 - For the first quarter (as of September
30, 2014) of its 2015 financial year Sangui BioTech International, Inc.
reports revenues from product sales and royalties in the amount of
USD73,470 (Q1/2013: USD26,527). This is an improvement of 73% as compared
with the fourth quarter of the previous financial year (as of June 30,
2014).
Research and development expenses amounted to USD93,103 (Q1/2014:
USD36,308). The increase is due to preparing and carrying out preclinical
trials aimed at demonstrating the functionality of Sangui's technology with
respect to various indications. The net loss attributable to shareholders
of the parent company came to USD194,168 (Q1/2013: USD172.202), the cash
outflow from operations during the quarter amounted to USD207,675 (Q1/2013:
USD189,860).
Primarily due to the net loss for the quarter, our stockholders' equity
decreased by USD75,501 from USD7,276 at June 30, 2014 to a stockholders'
deficit of USD68,225 at September 30, 2014.
The complete quarterly report on Form 10-QSB is available at www.sec.gov
and www.sanguibiotech.com.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de
---------------------------------------------------------------------
13.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
296450 13.11.2014
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte